Suppr超能文献

利托君治疗早产:一项荟萃分析。

Ritodrine in the treatment of preterm labour: a meta-analysis.

作者信息

Li Xiaomao, Zhang Yu, Shi Zhongjie

机构信息

Department of Obstetrics & Gynecology, Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510630, Guangdong Province, China.

出版信息

Indian J Med Res. 2005 Feb;121(2):120-7.

Abstract

BACKGROUND & OBJECTIVES: Results on the effect of ritodrine in the treatment of preterm labour are different all over the world. Therefore, a concrete conclusion cannot be drawn from a single randomized control trial (RCT). In this study, we selected a large number of RCTs worldwide on the treatment of preterm labour comparing ritodrine and placebo or magnesium sulfate and by applying meta-analysis, evaluated the effect of ritodrine in the treatment of preterm labour.

METHODS

We searched and identified 20 RCTs about ritodrine versus placebo, and ritodrine versus magnesium sulphate in the main medical data resources (MEDLINE, PubMed, CBMdisc, Cochrane Library and EMBASE) from January 1970 to December 2001 published in English and Chinese literature. We abstracted data about delay of gestation, gestational age at delivery, birth weight, severe neonatal respiratory system diseases, perinatal deaths, and administration to contraction-ceased interval, etc.

RESULTS

The odds ratio (OR) of 1 day (d) delay in 10 RCTs on ritodrine in preterm labour versus placebo was 2.95 (95%CI 2.15, 4.04), and OR of 2d delay was 1.91 (95%CI 1.49, 2.45), both differences were statistically significant. There were no significant difference on the OR of birth > or =37 wk, birth weight > or =2500 g, severe respiratory morbidity and perinatal mortality. The OR of 2d delay of four RCTs from abroad on ritodrine versus magnesium sulphate was 1.56 (95%CI 0.62, 3.94), and OR of 7d delay was 1.45 (95%CI 0.80, 2.62), both without significant difference. But the combined estimated rate difference (CERD) of side effects interruption rate was 12 per cent with significant difference. There were six Chinese RCTs on ritodrine and magnesium sulphate. The OR of 1d delay was 3.95 (95%CI 1.98, 7.88), and OR of neonatal death was 0.45 (95%CI 0.22, 0.93), both with significant difference. The average administration to contractionceased interval were 2.5 and 6.3 h, respectively, with CERD being -4.2 h.

INTERPRETATION & CONCLUSION: In treating preterm labour, ritodrine can significantly prolong a short interval more quickly but with relatively more side effects than magnesium sulphate. Stratified RCTs for different gestational ages and different labour stages should be designed for further study.

摘要

背景与目的

全世界关于利托君治疗早产的效果结果各异。因此,无法从单个随机对照试验(RCT)得出确切结论。在本研究中,我们选取了全球大量关于利托君与安慰剂或硫酸镁治疗早产的随机对照试验,并通过荟萃分析评估利托君治疗早产的效果。

方法

我们在1970年1月至2001年12月期间,检索并确定了主要医学数据资源(MEDLINE、PubMed、CBMdisc、Cochrane图书馆和EMBASE)中发表的20项关于利托君与安慰剂、利托君与硫酸镁对比的随机对照试验,这些试验发表于英文和中文文献中。我们提取了关于妊娠延迟、分娩时的孕周、出生体重、严重新生儿呼吸系统疾病、围产期死亡以及给药至宫缩停止间隔等数据。

结果

10项关于早产中利托君与安慰剂对比的随机对照试验中,妊娠延迟1天(d)的优势比(OR)为2.95(95%可信区间2.15,4.04),延迟2天的OR为1.91(95%可信区间1.49,2.45),两者差异均有统计学意义。出生孕周≥37周、出生体重≥2500克、严重呼吸系统疾病发病率和围产期死亡率的OR无显著差异。国外4项关于利托君与硫酸镁对比的随机对照试验中,延迟2天的OR为1.56(95%可信区间0.62,3.94),延迟7天的OR为1.45(95%可信区间0.80,2.62),两者均无显著差异。但副作用中断率的合并估计率差(CERD)为12%,差异有统计学意义。有6项关于利托君与硫酸镁对比的中国随机对照试验。延迟1天的OR为3.95(95%可信区间1.98,7.88),新生儿死亡的OR为0.45(95%可信区间0.22,0.93),两者差异均有统计学意义。给药至宫缩停止的平均间隔分别为2.5小时和6.3小时,CERD为 -4.2小时。

解读与结论

在治疗早产时,利托君能更快显著延长较短的间隔时间,但与硫酸镁相比副作用相对较多。应设计针对不同孕周和不同产程阶段的分层随机对照试验进行进一步研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验